Health Care Utilization for Patients with Triple Class Exposed Relapsed and Refractory Multiple Myeloma: Experience from a Canadian Center

Background: Multiple Myeloma (MM) is a plasma cell disorder characterized by the presence of remissions and relapses. The purpose of this project was to explore Canadian-specific real-world treatment patterns, and healthcare resource utilization (HCRU) in triple class exposed (TCE) relapsed/refractory MM (RRMM) patients in Canada. Methods: This is a retrospective observational cohort study using multiple administrative databases in Alberta, Canada. Outcomes were captured for TCE patients receiving a subsequent line of therapy (LOT) and included: treatment regimen details, time to next treatment (TTNT), overall survival (OS), and health care utilization. Results: Briefly, 567 TCE RRMM were identified. A median of 50 unique healthcare encounters were observed. In addition, 30.2% of readmissions were seen at 30 days from the start of next therapy in patients with TCE RRMM. On average at the patient level, there were 2 emergency department visits, 2 inpatient admissions, 51 total clinical visits and 5 infusion appointments. Overall, the average days spent on lab tests was 27 and the median duration of each inpatient admission was approximately 6-7 days. Median overall survival from initiating next line of therapy in TCE RRMM was 18.7 months (16-24.3 months). Conclusions: The present data provides further insights about healthcare resource utilization for patients with TCE RRMM in Alberta, Canada and may inform healthcare system planning as novel therapies continue to be developed for this patient population.

Jimenez-Zepeda:Pfizer: Honoraria; Takeda: Honoraria; Sanofi: Honoraria; GSK: Honoraria; BMS: Honoraria; Johnson & Johnson: Honoraria. Cheung:Johnson & Johnson: Research Funding. Mathew Stephen:Johnson & Johnson: Research Funding. Chan:Abbvie: Consultancy; Johnson & Johnson: Current Employment.